Cécile Chartier
Director/Board Member at CELLECTIS S.A.
Cécile Chartier active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CELLECTIS S.A. | Director/Board Member | 26/06/2023 | - |
NextVivo, Inc.
 NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | - | - |
Career history of Cécile Chartier
Training of Cécile Chartier
| Universite Louis Pasteur Strasbourg I | Doctorate Degree |
Statistics
International
| France | 3 |
| United States | 2 |
Operational
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CELLECTIS S.A. | Health Technology |
| Private companies | 1 |
|---|---|
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Technology Services |
- Stock Market
- Insiders
- Cécile Chartier
- Experience
